ArticleJournal of the American Heart Association2025
Metabolic Syndrome and Risk of Moyamoya Vasculopathy and Subsequent Stroke in Young Adults.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMoyamoya vasculopathy (MMV) is a rare cerebrovascular disease of unclear cause. In this study, we aimed to determine whether metabolic syndrome (MetS) is associated with the development of MMV and subsequent stroke risk in young adults.
methodsUsing a nationwide database, we retrospectively analyzed the data of 6 891 400 Korean adults aged 20 to 40 years who underwent health screening between 2009 and 2012. Participants were monitored until December 31, 2021, to identify patients newly diagnosed with MMV. We further examined the risk of ischemic and hemorrhagic stroke in patients newly diagnosed with MMV without prior stroke. Hazard ratios (HR) were calculated using multivariable Cox regression models adjusted for relevant confounders.
resultsOver a median follow-up of 9.65 years, 1754 individuals developed MMV. These participants exhibited significantly poorer baseline metabolic profiles, including a higher body mass index and a higher prevalence of diabetes, hypertension, and dyslipidemia (all
conclusionsMetabolic syndrome could substantially increase the risk of MMV development and subsequent stroke events in young adults. These findings emphasize the importance of managing metabolic health to prevent MMV and related neurological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.